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0959-8049/ª 2020 Elsevier Ltd. All righAbstract The novel coronavirus (CoV) pandemic is a serious threat for patients with cancer,
who have an immunocompromised status and are considered at high risk of infections. Data
on the novel CoV respiratory disease (coronavirus disease 2019 [COVID-19]) in patients with
cancer are still limited. Unlike other common viruses, CoVs have not been shown to cause a
more severe disease in immunocompromised subjects. Along with direct viral pathogenicity, in
some individuals, CoV infection triggers an uncontrolled aberrant inflammatory response,
leading to lung tissue damage. In patients with cancer treated with immunotherapy (e.g. im-
mune checkpoint inhibitors), COVID-19 may therefore represent a serious threat. After a
thorough review of the literature on CoV pathogenesis and cancer, we selected several shared
features to define which patients can be considered at higher risk of COVID-19. We combined
these clinical and laboratory variables, with the aim of developing a score to weight the risk of
COVID-19 in patients with cancer.
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ts reserved.Worldwide health services are facing the challenge of
the novel coronavirus (CoV) disease (coronavirus dis-
ease 2019 [COVID-19]) pandemic [1], which is widely
spreading rapidly and severely. Some categories of pa-
tients, including patients with cancer, are considered
more at risk than others. Cancer itself develops in an
immunocompromised field, supporting the evidence that
A. Indini et al. / European Journal of Cancer 135 (2020) 47e5048oncology patients are more at risk of infections, and this
risk is further increased by certain oncologic treatments
(e.g. chemotherapy, radiotherapy [RT]). Medical on-
cologists have arranged their daily clinical practice in
view of the current emergency, through the imple-
mentation of protective measures [2]. To date, no
evidence-based recommendations have been provided
owing to limited data of COVID-19 in oncology pa-
tients. Evidence from small case series suggest that
COVID-19 diffusion in patients with cancer is not
prominent as expected [3e6]. Rather, other comorbid-
ities (e.g. cardiovascular disease, diabetes, chronic
obstructive pulmonary disease) correlate with a higher
risk of infection and severe events [7].
Owing to the peculiar pathogenesis of CoV in
humans and to the mechanisms of action of novel
oncologic treatments, the link between CoV and patients
with cancer might not be straightforward. Unlike other
common viruses, CoVs have not been shown to cause a
more severe disease in immunocompromised subjects
[7]. Along with a direct viral pathogenicity, the host’s
immune response plays a crucial role in COVID-19. In
some individuals, CoV infection triggers an uncon-
trolled aberrant inflammatory response to external fac-
tors, which leads to lung tissue damage [8]. Since the
introduction of anticancer immunotherapy (e.g. immune
checkpoint inhibitors [ICIs]), most oncology patients
have changed their features of immunocompromisedTable 1
























Sex F Z 0
M Z 1
ECOG PS 0e1 Z 0
2 Z 1
Age <70 Z 0
70 Z 1
BMI <30 Z 0
30 Z 1
Comorbiditiesa No Z 0
Yes Z 1
Yes >1 Z 2
Concomitant steroid treatmentb No Z 0
Yes Z 1
Disease characteristics
Thoracic tumour No Z 0
Yes Z 1
History of thoracic RTc No Z 0
Yes Z 1
Treatment characteristics
Line of treatment Adjuvant Z 0
1 Z 1
Type of treatment HT/TKIs/TT/mAb Z 0
CT Z 1
IT/IT þ CT Z 2subjects. Rather, their immune system is somehow
‘boosted’ by the cancer treatment they receive. This
might translate into a distinct susceptibility of these
subjects towards CoV infections. The cross-interference
of CoV and ICIs may worsen the clinical course of
COVID-19, which, in turn, may intensify ICI-related
side-effects [9]. Altogether, this evidence suggests that
in patients treated with immunotherapy, COVID-19
(e.g. ICIs) may represent a serious threat [8].
The present article focuses on developing a score to
weight the risk of COVID-19 in patients with cancer.
The main issue raised by the pandemic is whether the
risk of COVID-19 outweighs that of cancer treatment
delay. In the present situation, oncologists need to
decide which kind of patient should start (or continue)
which kind of treatment and how much will this increase
the risk of complications in case of COVID-19 [10].
After a thorough review of the literature on CoV
pathogenesis and cancer, several shared features have
been selected to define which patients can be considered
at higher risk of complications in case of COVID-19.
The score includes clinical and laboratory variables,
as indicated in Table 1. Regarding the patient’s char-
acteristics, all recognised risk factors for COVID-19
were included: older age, presence of comorbidities,
obesity and sex [7]. Two more variables were included:
performance status (PS) according to the Eastern
Cooperative Oncology Group (ECOG) scale andduring the COVID-19 pandemic.




sider treatment delay in the presence of additional risk factors (e.g.
orbiditiesa) or to reduce hospital access.
sider telemedicine to monitor patients receiving an outpatient-
s treatment (e.g. oral anticancer drugs, HT).
4e6: intermediate risk
sider treatment delays (e.g. modification of treatment schedules)
patients with partial response to treatment.
sider treatment holidays for patients treated with IT or CT þ IT
6 months and/or with complete response to treatment.
efully monitor patients with history of irAEs.
‡7: high risk
ents need to be frequently monitored for symptoms, also with the
of telemedicine.
iations in laboratory values may indicate subclinical changes.
ntain treatment schedules only if safe administration is guaranteed;
r treatment administration depending on the type of treatment and
ase response.
id unnecessary procedures (e.g. radiologic examinations) to reduce
ital access.
Table 1 (continued )
Variables Score Categories of risk for patients and for treatment delays during COVID-19
diffusion
History of irAEsd No Z 0
Yes Z 1
Yes, pneumonitis Z 2
Laboratory values
NLR <5 Z 0
5 Z 1
LDH <ULN Z 0
ULN Z 1
CRP <ULN Z 0
ULN Z 1
BMI, body mass index; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; CT, chemotherapy; ECOG, Eastern Cooperative Oncology
Group; F, female; HT, hormonal therapy; irAEs, immune-related adverse events; IT, immunotherapy; LDH, lactate dehydrogenase; M, male;
mAb, monoclonal antibody; NLR, neutrophil-to-lymphocyte ratio; PS; performance status; RT, radiotherapy; TKIs, tyrosine kinase inhibitors;
TT, targeted therapy; ULN, upper limit of normal.
a Comorbidities include hypertension, cardiovascular disease, diabetes, chronic obstructive pulmonary disease and chronic systemic infections.
b Concomitant steroid treatment includes continuous therapy with a dose of >10 mg daily of prednisone equivalent, lasting for more than the 1-
month period.
c Only for patients with extrathoracic tumours.
d Only for patients treated with IT or IT þ CT.
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factor for outcomes, and the presence of poor ECOG PS
(i.e.  2) has been confirmed to be detrimental in pa-
tients with cancer and COVID-19 [6]. Long-lasting
treatment with high-dose corticosteroids, commonly
used as supportive therapy for patients with cancer and
potentially associated with an increased risk of oppor-
tunistic infections, seems to have a negative impact on
the COVID-19 outcome [5].
Regarding the underlying tumour characteristics,
limited available data suggest that lung cancer diagnosis
and ongoing thoracic RT at the time of the COVID-19
onset were common features of patients with severe
disease [3e6]. In our score, these two items are meant to
be included only once for patients with lung tumours. In
fact, thoracic RT is commonly used as treatment for
patients with lung tumours; however, this does not seem
to further increase the risk according to available data.
Nonetheless, patients with extrathoracic tumours
receiving thoracic RT (e.g. for palliative treatment of
metastases) should be considered at risk owing to the
potential radiation damage to the lung tissue.
Considering all the aforementioned issues, the type
and intent of oncologic treatment might have an
impact on the risk of COVID-19 complications. The
therapeutic setting (i.e. adjuvant versus treatment for
metastatic disease) has an impact owing to differences
in tumour burden and patients’ general conditions.
Immunotherapy or the combination of immunotherapy
and chemotherapy is considered high-risk treatments,
followed by chemotherapy and other anticancer drugs
(e.g. hormonal therapy, targeted agents). Among pa-
tients receiving immunotherapy, those with a history of
immune-related adverse events (irAEs) and/or disease
response to treatment might be even more at risk.
There is plenty of evidence that irAEs correlate with ahigher efficacy of immunotherapy, suggesting that an
adequate immune response harms both the tumour and
the host [11].
Common laboratory findings of patients with severe
COVID-19 are lymphopenia, high neutrophil-to-
lymphocyte ratio (NLR), high levels of inflammatory
markers (e.g. C-reactive protein) and lactate dehydro-
genase [1]. Polarisation of the immune response towards
a proinflammatory profile also correlates with lower
efficacy of immunotherapy and tumour progression, and
baseline NLR correlates with survival outcomes and
response to immunotherapy.
Altogether, these variables can be used to group
oncology patients in distinct classes of risk in the actual
COVID-19 emergency. The purpose of risk assessment
is to help clinicians in treatment decisions. Given the
lack of data in this field and the absence of a validation
in the clinical setting, the assumption of a precise role of
these variables is only conceptual. Prospective data
collection is needed to translate these observations in
clinical practice, with the aim of guiding risk-to-benefit
considerations and treatment decision in specific sub-
groups of patients. Customisation of cancer treatment
should be pursued, to provide patients with the best care
in this critical situation.
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